Hepatitis C Testing Market Expected to Surpass USD $1.67 Billion by 2029, Expanding at 6.2% CAGR

 Get 20% Off Market Intelligence Reports With Code ONLINE20 — Track Global Tariffs, Economic Shifts, and Sector Transformations

 

 What Is the Expected Market Growth Rate for the Hepatitis C Testing Market?
 The hepatitis c testing market size has grown strongly in recent years. It will grow from $1.24 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to the rise in hepatitis C prevalence, expansion of public health programs, rise in intravenous drug use, growing awareness of hepatitis C risks, and government funding for infectious disease control.
 
 The hepatitis c testing market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising demand for early disease detection, increasing healthcare access, growing emphasis on preventive healthcare, support from global health organizations, and government initiatives for hepatitis C elimination. Major trends in the forecast period include the adoption of multiplex diagnostic platforms, the integration of artificial intelligence (AI) in diagnostic tools, a shift toward home-based testing kits, increased collaboration for test development, and the development of low-cost testing solutions.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24559&type=smp
 
 What Are the Major Drivers Influencing the Hepatitis C Testing Market?
 The rise in the prevalence of hepatitis cases is expected to propel the growth of the hepatitis C testing market going forward. Hepatitis C is a viral infection that causes liver inflammation and can lead to serious liver damage if left untreated. Hepatitis cases are increasing mainly because low vaccination rates leave many individuals unprotected, facilitating the virus’s spread. Hepatitis C testing allows for early virus detection, facilitating prompt treatment to avoid liver damage and serious complications. It also identifies infected individuals to help prevent the spread and enhance disease control. For instance, in April 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization responsible for global public health, over 50 million people are living with chronic hepatitis C virus infection globally, with approximately 1.0 million new infections occurring each year. Therefore, the rising prevalence of hepatitis cases is driving the growth of the hepatitis C testing market.
 
 Which Segment Holds the Largest Share in the Hepatitis C Testing Market?
 The hepatitis c testing market covered in this report is segmented — 
 
 1) By Type: Antibody Tests, Nucleic Acid Tests, Genotyping Tests
 2) By Product: Test Kits, Instruments, Reagents, Consumables
 3) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests, Polymerase Chain Reaction, Next-Generation Sequencing
 4) By Application: Blood Screening, Viral Load Monitoring, Disease Diagnosis
 5) By End-User: Hospital-Based Laboratories, Stand-Alone Laboratories, Other End-Users
 
 Subsegments:
 1) By Antibody Tests: Enzyme Immunoassay (EIA), Recombinant Immunoblot Assay (RIBA), Rapid Diagnostic Tests (RDTs)
 2) By Nucleic Acid Tests (NATs): Quantitative Ribonucleic Acid (RNA) Tests, Qualitative Ribonucleic Acid (RNA) Tests, Transcription-Mediated Amplification (TMA), Reverse Transcription Polymerase Chain Reaction (RT-PCR)
 3) By Genotyping Tests: Line Probe Assay (LiPA), Sequencing-Based Assay, Real-Time Polymerase Chain Reaction (PCR)-Based Genotyping
 
 How Are Current Trends Influencing the Hepatitis C Testing Market Growth?
 Major companies operating in the hepatitis C testing market are focused on developing advanced solutions such as dual antigen-antibody diagnostic tests to enable more effective screening and monitoring of the infection. An antigen-antibody diagnostic test detects viral proteins (antigens) and immune response proteins (antibodies) to identify both active and past infections. This dual approach offers a thorough evaluation of the infection status. For instance, in July 2023, Roche Diagnostics India Pvt. Ltd., an India-based provider of diagnostic tests and systems, launched Elecsys HCV Duo, a fully automated immunoassay capable of simultaneously and independently detecting both HCV antigens and antibodies from one plasma or serum sample. This innovation enables early diagnosis, supports patient management, and aligns with India’s national strategy to eliminate hepatitis C through timely and comprehensive screening.
 
 Which Major Companies Are Operating in the Hepatitis C Testing Market?
 Major companies operating in the hepatitis c testing market are F. Hoffmann-La Roche Ltd., Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Quest Diagnostics Incorporated, Hologic Inc., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., SD Biosensor INC., QIAGEN N.V., DiaSorin S.p.A., Cepheid, Abcam Plc, OraSure Technologies Inc., Meridian Bioscience Inc., Trivitron Healthcare Private Limited, General Biologicals Corporation, Biogate Laboratories Ltd., Cosara Diagnostics Private Limited, BioGenex Life Sciences Private Limited, BIOGENIX INC. PVT. LTD. 
 
 Get the full hepatitis c testing market report here:
 https://www.thebusinessresearchcompany.com/report/hepatitis-c-testing-global-market-report
 
 Which Region Is Expected to Lead the Hepatitis C Testing Market by 2029?
 North America was the largest region in the hepatitis C testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis c testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company